- Home
- RMCO vs IXHL Comparison
RMCO vs IXHL Comparison
Compare RMCO & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMCO | IXHL |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 37.0M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RMCO | IXHL |
|---|---|---|
| Price | $2.83 | $3.54 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.8K | ★ 78.5K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,949,916.00 | $12,000.00 |
| Revenue This Year | $209.10 | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | N/A |
| 52 Week Low | $1.71 | $0.16 |
| 52 Week High | $5.00 | $6.39 |
Technical Indicators
Market Signals| Indicator | RMCO | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 67.22 |
| Support Level | $2.72 | $2.79 |
| Resistance Level | $3.04 | $3.68 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 61.62 | 91.67 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.